PRINCETON , N.J.--(BUSINESS WIRE)--
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that three abstracts highlighting the Company’s Listeria-based immunotherapy in combination with antibody-based immunotherapies have been accepted for poster presentation at the upcoming 2018 Keystone Symposia on Cancer Immunotherapies: Combinations (C5) taking place March 23-27, 2018 at the Queen Elizabeth Fairmont in Montreal.
|
Title: |
“Agonism of the CD137 co-stimulatory pathway synergizes with the Listeria monocytogenes-based immunotherapy, axalimogene filolisbac, to promote durable tumor regression in a murine HPV+ tumor model” |
|||||||
|
Poster Number: |
2001 | |||||||
|
Session: |
Poster Session 2 | |||||||
|
Date: |
March 25, 2018 | |||||||
|
Presenter: |
Rachelle E. Kosoff, Ph.D., Senior Scientist, Advaxis, Inc. | |||||||
|
Title: |
“Combination TIGIT blockade with Listeria-based immunotherapy enhances antigen-specific antitumor immunity” | |||||||
|
Poster Number: |
3015 | |||||||
|
Session: |
Poster Session 2 | |||||||
|
Date: |
March 25, 2018 | |||||||
|
Presenter: |
Daniel O. Villarreal, Ph.D., Principal Scientist, Advaxis, Inc. | |||||||
|
Title: |
“Targeting of CCR8 induces antitumor activity as a monotherapy that is further enhanced in combination with a Listeria-based immunotherapy” |
|||||||
|
Poster Number: |
3037 | |||||||
|
Session: |
Poster Session 2 | |||||||
|
Date: |
March 25, 2018 | |||||||
|
Presenter: |
Daniel O. Villarreal, Ph.D., Principal Scientist, Advaxis, Inc. | |||||||
“We are delighted to present these promising data before an audience of researchers and clinicians dedicated to elucidating the best possible combinations of targeted immunotherapies, to develop better treatments for patients with cancer. The data being presented highlight encouraging preclinical results, which show synergistic effects of a variety of antibody-based immunotherapies with our Lm Technology platform,” said Robert G. Petit, Ph.D., Executive Vice President and Chief Scientific Officer of Advaxis.
About Advaxis, Inc.
Advaxis, Inc. is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T cells to eliminate tumors. Advaxis has four franchises in various stages of clinical and preclinical development: HPV-associated cancers, neoantigen therapy, hotspot mutation therapy and prostate cancer.
To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, and YouTube.
Advaxis Forward-Looking Statement
This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis’ ability to develop and commercialize the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis’ proprietary immunotherapies. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis’ SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2017, which is available at www.sec.gov.
Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180129005112/en/
